The in silico functional analysis showed an association between the FGFR1 molecule and pazopanib, which a tyrosine kinase inhibitor recently approved for the treatment of renal cell carcinomas (RCC) [52]. The gene discussed is FGFR1; the disease is renal cell carcinoma.